The diagnostic and prognostic value of CD38 and CD49d expressions in chronic lymphocytic leukemia

Hendy, Olfat; Shafie, Mona A El; Allam, Maha; Motalib, Tawfik Abdel; Khalaf, Fatma A.; Gohar, Suzy

doi:10.4103/1110-1067.186409

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study male represented 52.5% of the patients` group while female represented 47.5%. This is in accordance with the findings of Hendy et al (13) . The higher prevalence of hematological malignancies among males could be attributed to fact that males are more exposed to the occupational agents that increase the risk of hematological cancers development (14) .…”

Section: Discussionsupporting

confidence: 94%

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Noreldin¹,

Zaiat²,

Ahmedy³

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: B-chronic-lymphocytic-leukemia (B-CLL) is a heterogeneous illness with a varied clinical history. Some individuals don't require therapy while others have an aggressive disease. Researchers discovered several prognostic biomarkers to help clinicians make decisions about whose patients will be in need to start treatment. Developing immunophenotyping markers such as CD69 and other serum markers such as TK and VEGF are evolving over time.Objective: This study aimed to assess relevance of CD69 as prognostic indicator in CLL cases and its association with Vascular-endothelial-growth factor (VEGF) and Thymidine-kinase (TK) activity. Methods: The research had 80 patients with B-CLL and 17 healthy controls. All subjects underwent routine laboratory investigations, flowcytometric analysis of CLL panel, CD38 and CD69 and TK activity and VEGF level by ELISA. Results: CD69 %, VEGF and TK were significantly higher in patients than in controls. Patients who required treatment had significantly higher CD69% and elevated levels of VEGF and TK than patients who were untreated. Correlation between CD69% with different parameters revealed significant positive correlation between CD69% and age, modified Rai staging, TLC, lymphocyte, B2 microglobulin, LDH, Coombs`test, receiving chemotherapy, CD 38/19%, VEGF and TK. CD69% at cut off levels of > 45% can significantly detect time to start chemotherapy with sensitivity and specificity of 88.89% and 77.27%. Regression analysis showed that age, modified Rai staging, lymphocyte count and HB level were independent variables that can predict CD69 expression. Conclusions: CD69, TK and VEGF could be considered as poor prognostic markers adding a new option for development of new prognosis score system.

show abstract

Section: Discussionsupporting

confidence: 94%

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Noreldin¹,

Zaiat²,

Ahmedy³

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…15 Also, the results of the current study was comparable to that documented in a study that has been done in Turkey regarding expression of CD19 (100%), CD5 (100%) and CD23 (96.7%), but there was difference in the expression of CD79b (38.8%) and FMC7 (42.1%), 25 the results of a study that has been done in Egypt showed almost identical results about the expression of CD19, CD5, CD23 whereas it showed more frequent expression for CD79b (73%) and FMC7 (25%). 26 The results of a study in Czech were consistent to the results of the current study about expression of CD19 (99.4%), CD5 (100%), CD79b (43.9%), but it reported different result about expression of CD23 (82.1%) and FMC7(2.9%), 27 Regarding the evaluation of sIg (IgM) expression in the present study revealed that the vast majority of CLL patients agreement with the results of study in Czech that reported the sIgM expressed in (10.6%), 27 The determination of the monoclonality of B lymphocyte based on the presence of monoclonal light chain restriction. In the present study, the monoclonality was determined in all CLL cases, monoclonal lambda light chain was more frequently expressed than monoclonal kappa light chain (50%), (11.3%) respectively, which were comparable to a study in Baghdad in terms of expression of monoclonal light chain type with less frequent rate, lambda (15%), kappa (7%), 13 CD20 was expressed in (88.2%) of CLL patients in the current study which was accordance to that reported previously in Erbil (75%), 15 as well as, in Turkey (93.4%), 25 the current study documented that CD200 was expressed in (97.1%) of the CLL patients that was accordance with the result of Falay et al study in Turkey in which CD200 expression was (96.7%), 28 as well as in a study from Czech was (98.3%), 27 In the present study, CD43 expressed in (54.4 %) of CLL patients that was less frequently expressed than the finding that documented by Falay et al in Turkey (98.3%), 28 The rate of CD38 expression among CLL patients in the present study was (26.5%), which was consistent with the result of Hasan et al (21%), 15 and Falay et al (24%), 28 In this series, CD25 expression was (33.8%) of CLL patients, it was comparable to the result of Starostka et al (39.3%).…”

Section: Final Diagnosismentioning

confidence: 99%

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Mazin Butrous,

Sadiq Muhammad

2023

Zanco J Med Sci

View full text Add to dashboard Cite

Background and objective: Chronic lymphocytic leukemia (CLL) is a clonal, mature B-cell neoplasm, its clinical features, cell morphology, and immunophenotyping are used to establish the diagnosis. Immunophenotyping by flow cytometry is the most accurate procedure for diagnosing CLL, there is no single marker exclusively expressed in CLL, however, a complex of immunophenotypic markers that incorporates several B-cell markers and assists in differentiating CLL from other mature B-cell neoplasms, the expression of these immunophenotypic markers is considered in the specific CLL scoring system (Moreue scoring system).this study aimed to assess the clinico – hematological features and immunophenotypic characteristics of CLL patients and to assess the role of immunophenotyping in the differential diagnosis of CLL. Methods: an observational prospective and retrospective study was carried out at Nanakaly hospital for blood diseases and oncology in Erbil city, Iraq. That was conducted on 100 patients newly diagnosed with mature B cell neoplasm which included 68 cases of CLL and 32 cases with other mature B cell neoplasm (MBN), usinga convenience sampling method. The study period was from the1st of September 2021 to the end of April 2022. An interview questionnaire was used to collect the study data from the patients. Results: The mean of age ± standard deviation of the CLL patients (58.85 ± 10.69) years and (66.2%) was male, The most frequent clinical presentations for CLL cases were fatigue (50%), lymphadenopathy (41.2%), and splenomegaly (41.2%), (50%) of CLL patients had anemia, thrombocytopenia was seen in (32.4%) and leukocytosis was seen (98.5%), all patients had lymphocytosis and (97%) had an absolute B lymphocyte count of more than 5 x109 /L. all the studied CLL patients expressed both CD45 and CD19 markers, the expression of the immunophenotypic markers was as following: CD5 (98.5%), CD23 (97.1%) and CD200 (97.1%), Half of the patients (50%) showed expression of monoclonal lambda light chain, sIgM (4.4%), CD20 (88.2%) and CD43 (54.4%) and CD38 (26.5%). The expression of the following marker had a significant role in the differentiation between CLL and other MBN: CD5, CD23, CD79b, FMC7, sIgM, CD200, and CD43. Conclusion: Our results have shown that the clinical presentations and hematological profile of Iraqi CLL patients were not significantly different from that of previous local and global studies, the distinct immunophenotyping, as well as it has been found that immunophenotyping is a promising method for supporting the clinical and morphological characterization of CLL.

show abstract

New insights into smudge cell percentage in chronic lymphocytic Leukemia: A novel prognostic indicator of disease burden

Mohamed

Safwat

2018

Egyptian Journal of Medical Human Genetics

View full text Add to dashboard Cite

The diagnostic and prognostic value of CD38 and CD49d expressions in chronic lymphocytic leukemia

Cited by 4 publications

References 0 publications

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Prognostic Relevance of CD69, Vascular Endothelial Growth Factor and Thymidine Kinase in B-Chronic Lymphocytic Leukemia

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

New insights into smudge cell percentage in chronic lymphocytic Leukemia: A novel prognostic indicator of disease burden

Contact Info

Product

Resources

About